2017 News Releases

December 14, 2017 - Puma Biotechnology Added to NASDAQ Biotechnology Index
Read

December 13, 2017 - Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

December 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Read

December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Patent Claims for Extended Adjuvant Treatment Upheld
Read

December 6, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Read

November 22, 2017 - Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
Read

November 13, 2017 - Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer
Read

November 9, 2017 - Puma Biotechnology Reports Third Quarter 2017 Financial Results
Results include the initial sales of NERLYNX® in the U.S.
Read

November 8, 2017 - Puma Biotechnology to Present at Stifel Healthcare Conference
Read

November 2, 2017 - Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance
Read

October 31, 2017 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

October 26, 2017 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

September 18, 2017 - Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
Read

September 8, 2017 - Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress
Data Demonstrates Continued Benefit from Neratinib after 5 years
Read

August 31, 2017 - Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference
Read

August 30, 2017 - Puma Biotechnology Announces Publication of Abstracts for ESMO 2017
Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer
Read

August 25, 2017 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

August 9, 2017 - Puma Biotechnology Reports Second Quarter 2017 Financial Results
Read

August 2, 2017 - Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)
Read

July 31, 2017 - Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States
Read

July 17, 2017 - U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

July 6, 2017 - Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial
Read

June 3, 2017 - Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting
Read

May 31, 2017 - Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference
Read

May 24, 2017 - Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib
Read

May 22, 2017 - Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting
Read

May 17, 2017 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting
Read

May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results
Read

May 9, 2017 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference
Read

April 17, 2017 - Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

April 4, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
Read

April 2, 2017 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting
Read

April 2, 2017 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting
Read

April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers
Caligor Opco LLC to Provide Regulatory and Logistical Management
Read

March 2, 2017 - Puma Biotechnology to Present at Cowen’s Health Care Conference
Read

March 1, 2017 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017
Read

March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272
Read

March 1, 2017 - Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results
Read

February 14, 2017 - Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference
Read

February 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read

January 6, 2017 - Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
Read

January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax